When it comes to fentanyl, it appears that both the problem and potential solution may originate from China.
The FDA has recently given the green light to Qamzova, the first non-opioid painkiller developed in China. This breakthrough medication, created by the Nanjing-based biotech company Delova, offers a promising tool in the fight against fentanyl-related overdose deaths.
Qamzova stands out as the world’s inaugural long-acting injectable analgesic, providing 24-hour pain relief with just one daily dose. Formulated with a high concentration of meloxicam, a non-steroidal anti-inflammatory drug (NSAID) in the same class as ibuprofen and aspirin, this medication has been hailed as a game-changer in pain management, as reported by the South China Morning Post.
The SCMP describes Qamzova as the best alternative to morphine, with clinical trials demonstrating its ability to significantly reduce morphine usage and pain levels following orthopedic and abdominal surgeries.
Approved for post-operative pain management in both the U.S. and China, Qamzova offers round-the-clock relief with a single injection, addressing the challenges associated with nighttime pain control. An anesthetist in Shanghai emphasized the significance of this advancement in clinical treatment.
According to Li Jianhua, a drug abuse expert in Yunnan, Qamzova has the potential to help alleviate the fentanyl crisis in the U.S. to some extent. However, further research is necessary to evaluate any long-term risks, such as the risk of addiction.
Qamzova, containing meloxicam, an NSAID, is considered a safer option for high-risk patients, including the elderly. Unlike traditional NSAIDs that require multiple doses, Qamzova provides effective pain relief without the high addiction risks and severe side effects associated with opioids, such as respiratory depression and nausea.
While Delova aims to address unmet medical needs in pain management, the approval of Qamzova also underscores China’s growing innovation in the pharmaceutical industry. This milestone comes amidst ongoing tensions between the U.S. and China regarding fentanyl, with Washington accusing Beijing of not taking adequate measures to curb the export of precursor chemicals—a claim that China refutes.
Loading…